文献速递特殊人群用药

整合离体胎盘灌注数据与PBPK模型预测妊娠期艾司西酞普兰、舍曲林和帕罗西汀的母胎暴露

Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling.
PubMed 文献 · Clin Pharmacokinet · 2025-09-27

本研究利用离体人胎盘灌注实验数据构建妊娠期PBPK模型,预测三种SSRIs的母胎暴露。模型准确预测了母体和胎儿浓度时间曲线,发现妊娠期母体浓度下降,且胎儿暴露因药物而异。

要点

  • 妊娠期舍曲林、艾司西酞普兰和帕罗西汀的母体总浓度和游离浓度均下降。
  • 妊娠晚期母体残留浓度下降幅度:舍曲林56%和43%,艾司西酞普兰55%和49%,帕罗西汀90%和88%(总浓度和游离浓度)。
  • 脐血与母体血浆AUC比值(fm AUC)在妊娠晚期分别为舍曲林0.45、艾司西酞普兰0.91、帕罗西汀0.58。

核心结论

  • 整合离体胎盘灌注数据的PBPK模型能准确定量预测舍曲林、艾司西酞普兰和帕罗西汀的母体和胎儿暴露。

研究设计与样本

  • 利用离体人胎盘灌注实验数据,通过Monolix混合效应模型估计经胎盘参数,整合至Simcyp妊娠PBPK模型,并与文献观察数据比较评估后模拟不同妊娠期的母体PK和胎儿暴露。

主要发现

  • 妊娠PBPK模型准确预测了三种SSRIs的母体和胎儿浓度时间曲线。
  • 模拟显示妊娠期三种SSRIs的母体总浓度和游离浓度均下降。
  • 妊娠晚期母体残留浓度下降:舍曲林总浓度56%、游离浓度43%;艾司西酞普兰总浓度55%、游离浓度49%;帕罗西汀总浓度90%、游离浓度88%。
  • 妊娠晚期脐血与母体血浆AUC比值(fm AUC)分别为舍曲林0.45、艾司西酞普兰0.91、帕罗西汀0.58。

临床怎么用

  • 该模型有助于理解妊娠期生理变化对SSRIs药代动力学的影响,支持妊娠期抑郁症的循证药物治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Depression is common in pregnant women, and selective serotonin reuptake inhibitors (SSRIs) are the most widely used antidepressants during pregnancy. Pregnancy is a period of major physiological changes that impact drug pharmacokinetics (PK). To date, there is limited information about the placental transfer of antidepressants, and differences in fetal exposure between drugs are poorly characterized. AIMS: We aimed to develop physiologically based pharmacokinetic (PBPK) models to assess maternal and fetal exposure to sertraline, escitalopram and paroxetine across pregnancy. METHODS: Transplacental parameters from ex vivo human placenta perfusion experiments were estimated using mixed-effects modeling in Monolix and integrated in pregnancy PBPK models in Simcyp PBPK Simulator. After evaluation of the models by comparison with observed data from literature, maternal PK profiles and fetal exposure at different trimesters of pregnancy were simulated. RESULTS: The pregnancy PBPK models accurately predicted maternal and fetal concentration time-courses of SSRIs. Simulations showed a decrease in maternal concentrations during pregnancy for all three SSRIs, affecting both total and unbound concentrations. In the third trimester, residual concentrations were predicted to decrease by 56% and 43% for sertraline, 55% and 49% for escitalopram, and 90% and 88% for paroxetine, for total and unbound concentrations respectively. Cord blood-to-maternal plasma area-under-curve (fm AUC) ratios over 24 h were calculated based on model predictions. By late pregnancy, fm AUC ratios were 0.45 for sertraline, 0.91 for escitalopram, and 0.58 for paroxetine. CONCLUSIONS: Quantitative prediction of antidepressants exposure using PBPK modeling integrating ex vivo data will help to better understand the impact of pregnancy-related physiological changes on the PK of these drugs and support evidence-based pharmacotherapy for depression during pregnancy.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Préta LH, Bouazza N, Foissac F, et al. Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2025. PMID: 41014441. doi:10.1007/s40262-025-01574-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。